Resmed Willing to Cut Underperforming Assets

Dow Jones

Jul 09

0106 GMT - ResMed's bulls at Jarden see the divestment of its MatrixCare business as a good example of the breath-tech supplier's willingness to recycle capital from business units that have not performed to expectations. With an unchanged overweight rating on ResMed's Australia-listed stock, the Jarden analysts write in a note that using proceeds from the US$490 million divestment to implement an accretive buyback shows good capital management. They trim their target price by 5.8% to 40.20 Australian dollars on earnings revisions and currency updates, but anticipate upside to EPS forecasts from a potential increase to the buyback. Shares are down 3.3% at A$30.17. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 08, 2026 21:06 ET (01:06 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2650408912"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650408912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650408912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 09:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650408912","market":"hk","top_or_hot":-1,"title":"Resmed Willing to Cut Underperforming Assets","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0106 GMT - ResMed's bulls at Jarden see the divestment of its MatrixCare business as a good example of the breath-tech supplier's willingness to recycle capital from business units that have not performed to expectations. With an unchanged overweight rating on ResMed's Australia-listed stock, the Jarden analysts write in a note that using proceeds from the US$490 million divestment to implement an accretive buyback shows good capital management. They trim their target price by 5.8% to 40.20 Australian dollars on earnings revisions and currency updates, but anticipate upside to EPS forecasts from a potential increase to the buyback. Shares are down 3.3% at A$30.17. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 21:06 ET (01:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Resmed Willing to Cut Underperforming Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResmed Willing to Cut Underperforming Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-09 09:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0106 GMT - ResMed's bulls at Jarden see the divestment of its MatrixCare business as a good example of the breath-tech supplier's willingness to recycle capital from business units that have not performed to expectations. With an unchanged overweight rating on ResMed's Australia-listed stock, the Jarden analysts write in a note that using proceeds from the US$490 million divestment to implement an accretive buyback shows good capital management. They trim their target price by 5.8% to 40.20 Australian dollars on earnings revisions and currency updates, but anticipate upside to EPS forecasts from a potential increase to the buyback. Shares are down 3.3% at A$30.17. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 21:06 ET (01:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGHT","symbol_name":"LANGAR GLOBAL HEALTHTECH ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2650408912","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650408912","pubTimestamp":1783559160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0106 GMT - ResMed's bulls at Jarden see the divestment of its MatrixCare business as a good example of the breath-tech supplier's willingness to recycle capital from business units that have not performed to expectations. With an unchanged overweight rating on ResMed's Australia-listed stock, the Jarden analysts write in a note that using proceeds from the US$490 million divestment to implement an accretive buyback shows good capital management. They trim their target price by 5.8% to 40.20 Australian dollars on earnings revisions and currency updates, but anticipate upside to EPS forecasts from a potential increase to the buyback. Shares are down 3.3% at A$30.17.  Dow Jones NewswiresJuly 08, 2026 21:06 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","RMD.AU":"Resmed DRC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4504":"桥水持仓","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK7501":"新冠治疗股","BK4588":"碎股","RMD":"瑞思迈","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK7007":"医疗保健设备"},"translate_title":"瑞思迈愿意削减表现不佳的资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":0.9,"LGHT":0.6,"RMD.AU":0.9},"content_text":"0106 GMT - ResMed's bulls at Jarden see the divestment of its MatrixCare business as a good example of the breath-tech supplier's willingness to recycle capital from business units that have not performed to expectations. With an unchanged overweight rating on ResMed's Australia-listed stock, the Jarden analysts write in a note that using proceeds from the US$490 million divestment to implement an accretive buyback shows good capital management. They trim their target price by 5.8% to 40.20 Australian dollars on earnings revisions and currency updates, but anticipate upside to EPS forecasts from a potential increase to the buyback. Shares are down 3.3% at A$30.17. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2026 21:06 ET (01:06 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}